Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515

Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510

SECRETARY OF THE SENAI: 99 AUG 12 PH 12: 49

H.O.

## LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

t. Registrant Name		Į.	
Fox, Bennett & Turner			
2. Address Check if different than previously reported 750 17th Street, N.W., State 1100, Wash	ington, DC 20006		
3. Principal Place of Business (if different from line 2)		**************************************	
City: State/	Zip (or Country)		
4. Contact Name Telephone	E-mail (optional)	5. Senate #D # 15270-214	
Albert Cacozza (202) 778-2300	 	6. House iD#	
7. Climit Name Self Serono Laboratories			
TYPE OF REPORT 8. Year 1999 Midyear  9. Check if this filing amends a previously filed version of this  10. Check if this is a Termination Report □ ⇔ Termination	report 🔘	End (July 1-December 31)	
INCOME OR EXPENSES - Complete Either	r Line 12 OR Line 13		
12. Lobbying Firms	13. Organiz	ations.	
INCOME relating to lobbying activities for this reporting period was:	EXPENSES relating to lobbying act period were:	ivities for this reporting	
Less than \$10,000 🖸	Less than \$10,000 🚨		
\$10,000 or more \( \sigma \) \( \sigma \) \( \frac{40,000}{\text{lacome (nearest \$20,000)}} \)  Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	\$10,000 or more		
	14. REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of options.		
	Method A. Reporting amounts using LDA definitions only		
	Method B. Reporting amounts under section 6033(b)(8)of the Internal Revenue Code		
	Method C. Reporting amounts under section 162(e) of the Internal Revenue Code		
Signature			
Printed Name and Title			

nformation as requested. Attach additi			
5. General issue area code MED	(one per page)		
6. Specific lobbying issues			
Orphan Drug Act			
7. House(s) of Congress and Federal	agencies contacted	Check if None	
U.S. Senate U.S. House of Representati	íves		
Fooddand Drug Administrati			
18. Name of each individual who acte	d as a lobbyist in this issue:		
Name		Covered Official Position (if applicable)	
Alan R. Bennett			***************************************
Michael D. Petty			
	.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		
	- "		
		***************************************	***************************************
**************************************			
,		77FF-1	·····
•	*		
atories, Inc., so too Ares-Se	s, either law or rego rono SA will benefit	Gabove Check if None plations, commercially benefit s  Ares-Serono is the parent of the commercial success of its	ombany o
Signature		Date	
		ę.	

LOBBYING ACTIVITY. Select as many codes as necessa engaged in lobbying on behalf of the client during the report information as requested. Attach additional page(s) as need	ing period. Using a separate page for each code,	gistrant provide
15. General issue area code <u>NAM</u> (one per page)		
16. Specific lobbying issues		
	***************************************	
17. House(s) of Congress and Federal agencies contacted	Check if None	
: -		
18. Name of each individual who acted as a lobbyist in this	issue area	
Name	Covered Official Position (if applicable)	
	u.,	
	į.	
	(	
	[	
'M''		
		, !
19. Interest of cach foreign entity in the specific issues listed on the degree that public policies, either law or ratories, Inc., so too Ares-Serono SA will be no Laboratories, Inc., and the parent benefit Signature	regulations, commercially benefit Sero	ann af
Printed Name and Title Alan R. Bennett, Partner		

A 16